Parkinson's Disease Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Men and women between 50 and 85 years old at the time of the on-site visit (those aged 81–85 will be considered individually by the lead researcher).
- People who have given their signed agreement to take part in the study.
- People who are willing and able to follow the study procedures, including swallowing a special study capsule, and attending required assessments.
- People who are able to swallow a size-00 capsule (25mm long) while in the "off" state (when Parkinson's symptoms are less controlled).
- People who have been diagnosed with idiopathic Parkinson's disease (clinically probable), including confirmed responsiveness to levodopa medication.
- People who are currently taking an immediate-release levodopa medicine during the day at a stable dose for at least 2 months before joining the study.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have a gut or digestive condition that may prevent a swallowed capsule from passing through and leaving the body normally.
- People who have taken any medications in the week before the on-site visit that could significantly affect how the digestive system moves, unless those medications are part of their regular ongoing treatment.
- People with a history of difficulty swallowing (affecting the mouth or throat), or any other swallowing disorder that could risk the capsule being inhaled into the airway (for example, a score above 4 on a swallowing difficulty questionnaire).
- People who have received, or are currently receiving, strong anti-inflammatory or immune-suppressing medicines within 2 months of the on-site visit — such as DMARDs, biologics, or oral steroids — except for occasional use of certain anti-inflammatory medicines (NSAIDs) or a specific bowel treatment called mesalazine (5-ASA).
- People who have had an active cancer diagnosis within the past 5 years.
- People who have a clinically significant problem with their immune system, as determined by the investigator.
- People who have used antibiotics (other than those applied directly to the skin or a local area) within 12 weeks before the on-site visit, or who have ever had a faecal microbiota transplant (a procedure involving transfer of gut bacteria).
- People who have used prebiotic or probiotic supplements within 2 weeks before the on-site visit.
- People who have a history of dementia.
- People who have insulin-dependent diabetes.
- People currently experiencing a psychosis episode, as assessed by the clinical team.
- People who are pregnant.
- People with current alcohol or drug abuse.
- People who are currently receiving deep brain stimulation treatment or using Duodopa/Lecigon (a gel-based levodopa delivery system).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 4032108726
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Change of Part 3 score of the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) on L-dopa challenge test
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.